Biotech

• Anthropic anunció la adquisición de Coefficient Bio, una startup de IA con sede en EE. UU. especializada en modelado biológico, el 27 de abril de 2026. • El acuerdo tiene como objetivo integrar las herramientas de IA de diseño de proteínas de Coefficient con los modelos Claude de Anthropic para aplicaciones avanzadas en el descubrimiento de fármacos. • Este movimiento posiciona a Anthropic en el competitivo espacio de la biotecnología de IA en medio de inversiones crecientes, acelerando potencialmente los avances en medicina personalizada.

• Anthropic acquired Coefficient Bio, a startup founded eight months ago with fewer than 10 employees, for roughly $400 million in shares, despite it having no product or revenue. • The platform uses AI for pharmaceutical tasks like drug research planning and identifying new drug opportunities, positioning Anthropic's models for scientific discovery in life sciences. • This bet signals a strategic push into AI-driven biotech, potentially accelerating drug development amid growing competition in applied AI verticals.

Biotech firm Immutep Ltd. crashed more than 80% on March 13, 2026, becoming one of the biggest decliners amid a mixed US market session pressured by geopolitical fears. The plunge contrasted with gains in AI leaders like Intel (+1.7%), Tesla (steady at $395), and Nokia (+1.4%), highlighting sector rotation. This extreme volatility amplifies risks in biotech amid elevated VIX at 26.49 and weekly index losses. Investors may monitor clinical trial updates or funding news for rebound potential.